Project description
A drug discovery platform for precision medicine
The gold standard treatment of ovarian cancer comprises platinum-based chemotherapeutic agents that bind DNA and cause cells to undergo apoptosis. However, the frequent emergence of drug resistance causes patients to relapse. Therefore, new treatment strategies are required. To address this unmet medical need, the EU-funded OvCaPreMed project will develop a pipeline for the identification of drugs and drug combinations capable of overcoming platinum resistance. The cutting-edge technology will combine tissue engineering, chemical synthesis and microfluidic technology. It will help screen drugs in patients with relapsed ovarian cancer who have exhausted all other treatment options, offering tailored alternatives.
Objective
OvCa for Precision Medicine: Personalized Ovarian Cancer Treatment using High-Throughput and Microfluidic Drug Screening.
The main issue with current Ovarian Cancer (OvCa) treatments is the eventual resistance to standard platinum-based chemotherapy, which ultimately leads patients to relapse. Identifying drugs and drug combinations that overcome platinum resistance by new treatment strategies is an unmet medical need in OvCa patients that I plan to address with our technology pipeline as a Proof-of-Concept. I, Deepak Balaji Thimiri Govinda Raj, under the supervision and mentorship of Dr. Dalu Mancama (Precision Medicine) and Dr. Janine Scholefield (Synthetic Biology) at CSIR South Africa along with Prof. Nicholas Dunne and Dr. David Kinahan at Dublin City University (DCU), propose developing a cutting-edge technology pipeline with which I will identify and screen drugs and drug combinations for relapsed OvCa patients who have exhausted all other treatment options. I will use OvCa patient samples to validate the drug screening pipeline as a Proof-of-Concept. Our technology pipeline includes strategies where I will combine tissue engineering (Prof. Nicholas Dunne’s team) with microfluidic technology (Dr. David Kinahan, DCU), Chemstress platform (Dr. Jerry Clifford, ValitaCell) and my expertise in chemical biology accumulated during my PhD and three post-doctoral placements. Using this pipeline, we aim to identify drug combinations that can overcome platinum resistance and ultimately provide tailored-specific therapy options for OvCa patients. We intend our technologies to provide clinically relevant drug combinations information to oncologists.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- natural sciences biological sciences synthetic biology
- natural sciences chemical sciences inorganic chemistry transition metals
- medical and health sciences medical biotechnology tissue engineering
- medical and health sciences clinical medicine oncology
- medical and health sciences health sciences personalized medicine
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-MSCA-IF-2019
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
9 Dublin
Ireland
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.